Menu

Obama Administration Eases Marijuana Research Requirements

Scientists wishing to study marijuana’s health effects may now forgo a review by Public Health Services.

Jun 29, 2015
Amanda B. Keener

MARK, FLICKR

Studying the health effects of marijuana just got a little easier. In a statement released last week (June 23), The Department of Health and Human Services (HHS) announced the elimination of one of four regulatory hurdles that researchers must clear in order to study medical applications for the drug.

“The president has often said that drug policy should be dictated by unimpeded science instead of ideology, and it’s great to see the Obama administration finally starting to take some real action to back that up,” Tom Angell of the pro-legalization group, Marijuana Majority told the Washington Post.

According to the Washington Post, HHS determined that the regulatory step, which entailed a review by Public Health Services (PHS) was redundant with another required review by the Food and Drug Administration. Drug Policy News reports that the Clinton administration installed the PHS review to keep the growing field of marijuana research under strict controls.

“I think it's a sensible change; but people are being delusional if they think this will result in a flood of research on the drug,” Kevin Sabet of the anti-legalization group, Smart Approaches to Marijuana, told the Washington Post.

Marijuana researchers still face other unique barriers, such as the requirement to obtain all marijuana plants from the National Institute on Drug Abuse (NIDA).

“This is progress, but the White House should also end the NIDA’s unique monopoly on marijuana production, and allow private entities to grow marijuana, thus facilitating even more important research,” Bill Piper, the Director of Drug Policy Alliance’s Office of National Affairs, told Drug Policy News.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.
Corning Introduces New 1536-well Spheroid Microplate
Corning Introduces New 1536-well Spheroid Microplate
High-throughput spheroid microplate benefits cancer research, drug screening